Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS
· Real-Time Price · USD
8.16
0.00 (0.00%)
At close: Jun 24, 2025, 3:59 PM
Regulus Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 302K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 170K | n/a | 89K | 81K | 76K | 56K | 47K | 48K | 33K | 32K | 31K | 26K | 4.41M | 38K | 45K | 335K |
Gross Profit | n/a | 170K | n/a | -89K | -81K | 226K | -56K | -47K | -48K | -33K | -32K | -31K | -26K | -4.41M | -38K | -45K | -335K |
Operating Income | -10.54M | -13.75M | -15.21M | -12.26M | -8.83M | -8.3M | -8.13M | -7.32M | -7.37M | -6.93M | -7.56M | -7.17M | -6.57M | -6.96M | -8.42M | -6.64M | -5.8M |
Interest Income | n/a | 968K | 1.15M | 1.28M | 438K | 353K | 438K | 471K | 415K | 333K | 187K | 79K | 6K | 41K | 1K | 821K | 1K |
Pretax Income | -9.63M | -12.79M | -14.06M | -11.04M | -8.47M | -8.06M | -7.82M | -7.01M | -7.14M | -6.79M | -7.55M | -7.26M | -6.72M | -7.13M | -8.63M | -6.03M | -6.01M |
Net Income | -9.63M | -12.79M | -14.06M | -11.04M | -8.47M | -8.06M | -7.82M | -7.01M | -7.09M | -6.8M | -7.54M | -7.34M | -6.72M | -7.13M | -8.63M | -6.03M | -6.01M |
Selling & General & Admin | 3.72M | 4.07M | 3.86M | 3.93M | 2.79M | 2.52M | 2.64M | 2.34M | 2.44M | 2.22M | 2.25M | 2.47M | 2.89M | 2.55M | 2.5M | 2.49M | 2.48M |
Research & Development | 6.82M | 9.67M | 11.35M | 8.24M | 6.04M | 5.71M | 5.49M | 4.98M | 4.92M | 4.71M | 5.31M | 4.71M | 3.68M | 4.41M | 5.92M | 4.15M | 3.32M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -173K | n/a | n/a | -215K |
Operating Expenses | 10.54M | 13.75M | 15.21M | 12.17M | 8.83M | 8.22M | 8.13M | 7.32M | 7.37M | 6.93M | 7.56M | 7.17M | 6.57M | 6.96M | 8.42M | 6.64M | 5.8M |
Interest Expense | -17K | 13K | 5K | 58K | 81K | 114K | 137K | 168K | 185K | 196K | 175K | 162K | 155K | 214K | 210K | 216K | 216K |
Selling & Marketing Expenses | n/a | n/a | n/a | -20K | n/a | -20K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 14M | 15.21M | 12.26M | 8.83M | 8.3M | 8.13M | 7.32M | 7.37M | 6.93M | 7.56M | 7.17M | 6.57M | 6.96M | 8.42M | 6.64M | 5.8M |
Income Tax Expense | n/a | n/a | n/a | 1K | -81K | n/a | -56K | 1K | -45K | 1K | -12K | 83K | 1K | n/a | 1K | 1K | n/a |
Shares Outstanding (Basic) | 66.17M | 65.5M | 65.47M | 64.47M | 28.75M | 20.22M | 19.63M | 19.1M | 16.84M | 16.84M | 14.97M | 14.61M | 14.6M | 10.69M | 8.7M | 7.72M | 7.13M |
Shares Outstanding (Diluted) | 66.17M | 65.5M | 65.47M | 64.47M | 28.75M | 20.22M | 19.63M | 19.1M | 16.84M | 16.84M | 14.97M | 14.61M | 14.6M | 10.69M | 8.7M | 7.72M | 7.13M |
EPS (Basic) | -0.15 | -0.2 | -0.21 | -0.17 | -0.29 | -0.4 | -0.4 | -0.37 | -0.42 | -0.4 | -0.5 | -0.5 | -0.46 | -0.67 | -0.99 | -0.78 | -0.84 |
EPS (Diluted) | -0.15 | -0.2 | -0.21 | -0.17 | -0.29 | -0.4 | -0.4 | -0.37 | -0.42 | -0.4 | -0.5 | -0.5 | -0.46 | -0.67 | -0.99 | -0.78 | -0.84 |
EBITDA | -10.54M | -12.69M | -13.97M | -10.89M | -8.31M | -7.87M | -7.63M | -6.8M | -6.91M | -6.57M | -7.34M | -7.07M | -6.54M | -6.92M | -8.38M | -5.77M | -5.46M |
EBIT | n/a | -12.78M | -14.06M | -10.98M | -8.39M | -7.95M | -7.69M | -6.84M | -6.95M | -6.6M | -7.38M | -7.1M | -6.56M | -6.92M | -8.42M | -5.82M | -5.8M |
Depreciation & Amortization | n/a | 87K | 90K | 89K | 81K | 76K | 56K | 47K | 48K | 33K | 32K | 31K | 26K | 41K | 38K | 45K | 335K |